Elevance Health Inc (ELV) FinancialsELVFinancialElevance Health Inc

Elevance Health Inc (ELV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Premiums, accounting for 81.8% of total sales, equivalent to $41.02B. Other significant revenue streams include Product revenue and Service fees. Understanding this composition is critical for investors evaluating how ELV navigates market cycles within the Managed Healthcare industry.

Evaluating the bottom line, Elevance Health Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.56%, while the net margin is 2.88%. These profitability ratios, combined with a Return on Equity (ROE) of 11.20%, provide a clear picture of how effectively ELV converts its operational activities into shareholder value.

In the context of the broader market, ELV competes directly with industry leaders such as CI and HUM. With a market capitalization of $86.55B, it holds a leading position in the sector. When comparing efficiency, ELV's gross margin of N/A stands against CI's 8.58% and HUM's N/A. Such benchmarking helps identify whether Elevance Health Inc is trading at a premium or discount relative to its financial performance.

Elevance Health has shown strong revenue growth, with Q2 2026 revenue at $50.47 billion, up from $49.77 billion in Q1 2026. The net income for Q2 2026 was $1.46 billion, reflecting a solid profit margin of 2.88%.